Results 1 to 10 of about 701,268 (244)
Acta OncologicaBackground and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg +10 more
doaj +4 more sources
Comparison of PFS-OS between two treatment methods (surgery and then chemotherapy compared with neoadjuvant and then surgery) in patients with endometrial cancer: a retrospective study [PDF]
Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2023 Introduction: Endometrial cancer is one of the common diseases among women, which causes the death of many women in the world every year. The survival of patients and their response to treatment is determined based on clinical conditions and the stage of
Narjes Afrooz +2 more
doaj +1 more source
High-dose-rate endobronchial brachytherapy in the management of advanced lung cancer - comparison according to the presence of lung atelectasis [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2021 Introduction/Objective. Locally advanced lung cancer is often accompanied by atelectasis of either a part or the entire lung. The aim of this study was to establish the benefits of brachytherapy on the patients’ quality of life, the length of the ...
Bojović Marko +7 more
doaj +1 more source
European Urology Open Science, 2023 The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer ...
Giuseppe Fallara +8 more
doaj +1 more source
Prognostic impact of p16 and p53 gene expressions in stage 1a epithelial ovarian cancer [PDF]
Obstetrics & Gynecology Science, 2020 Objective Epithelial ovarian cancer (EOC) is rarely detected at stage 1a. Most of the patients have a good prognosis and there are limited factors that affect their survival. In the present study, we evaluated the p16 and p53 gene expressions of stage 1a
Emre Günakan +5 more
doaj +1 more source
Progression‐free survival in oncology: Caveat emptor! [PDF]
Basic & Clinical Pharmacology & Toxicology, 2018 AbstractOverall survival (OS) is the undisputed gold standard efficacy end‐point in cancer drug trials. It is with growing concern that we observe how progression‐free survival (PFS) gains ground as surrogate end‐point in its place. PFS has appeal because it is resource‐efficient, but it has severe shortcomings.
Bergmann, Troels K; id_orcid 0000-0001-8313-0721 +4 more
openaire +2 more sources
An Audit Strategy for Progression-Free Survival [PDF]
Biometrics, 2011 In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression-free survival (PFS) is one such endpoint.
Dodd, Lori E. +4 more
openaire +3 more sources
Indonesian Journal of Cancer, 2021 Background: This study was conducted to determine the association between clinical characteristics, progression-free survival (PFS), and 3-year survival in patients with epithelial ovarian cancer who underwent surgery in 2016-2017 at RSUD Dr.
Brahmana Askandar Tjokroprawiro +2 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect ...
Ziqi Ye +6 more
doaj +1 more source
A nomogram to predict the progression-free survival of clival chordoma [PDF]
Journal of Neurosurgery, 2021 OBJECTIVE Chordoma shows poor patient prognosis because of its high recurrence rate. Even though many clinical factors and biomarkers are reported to be associated with prognosis, no prediction model has been applied clinically.
Yixuan, Zhai +6 more
openaire +2 more sources